Partnership focused on validation of novel Organ-on-a-Chip infection models Human-relevant single and multi-organ SARS-CoV-2 infected models
CN Bio expands service offering to support oncology drug discovery
New Oncology Service supports unique in vitro investigations into the PK/PD relationship Harnesses CN Bio’s proprietary PhysioMimix® PK system
CN Bio licenses human gut organ microbiome modelling tool from MIT and Northeastern University
Enables accurate modelling of the human colon and the mucosal barrier Provides new insights to the relationship between human microbiome and effect
Lonza and CN Bio announce distribution agreement
Lonza and CN Bio announce distribution agreement providing pre-validated hepatocytes for use on innovative Organ-on-a-chip range Through a new
CN Bio’s PhysioMimix® adopted by King’s College London to investigate chronic liver disease
Next generation organ-on-a-chip (OOC) technology to be used to investigate the human gut microbiome for improving outcomes for patients with liver
CN Bio FDA collaboration expanded
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to
Introducing the PhysioMimix® OOC Multi-Organ Microphysiological System
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the
CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ
CN Bio’s PhysioMimix® technology receives FDA recognition
FDA publication demonstrates advantages of PhysioMimix® in drug safety and metabolism applications, over standard techniques Represents the first